Breaking News

Dyadic to Develop Cell Lines for COVID-19 Vaccine Candidates

Selected by the Frederick National Laboratory to engineer proprietary C1 cell lines

By: Contract Pharma

Contract Pharma Staff

Dyadic International Inc., a global biotechnology company, has been selected by the Frederick National Laboratory to engineer its patented and proprietary C1 cell lines to produce a number of COVID-19 vaccine candidates which will be utilized by the Vaccine Research Center (VRC) part of the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health.   “We are proud that our C1 technology has the potential to support the Vaccine Research Center COVID...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters